Bayer to invest 2 billion euros in drug production over next 3 years

FILE PHOTO: Logo of Bayer AG at a plant of the German pharmaceutical and chemical maker in Wuppertal
FILE PHOTO: A bridge is decorated with the logo of a Bayer AG, a German pharmaceutical and chemical maker in Wuppertal, Germany August 9, 2019. REUTERS/Wolfgang Rattay

March 31, 2022

FRANKFURT (Reuters) – German drugmaker Bayer said it would invest around 2 billion euros ($2.23 billion) at pharmaceutical manufacturing sites over the next three years, mainly to bolster production of biotechnology drugs as well as cell and gene therapies.

The sites to be upgraded include Berkeley, California, as well as Berlin, Leverkusen and Bergkamen in Germany.

In addition, Bayer will transfer a manufacturing plant in Sao Paulo Cancioneiro, Brazil, as well as parts of the infrastructure and services at the German sites in Bergkamen, Wuppertal and Berlin to new operators.

($1 = 0.8956 euros)

(Reporting by Ludwig Burger, Editing by Miranda Murray)